OSRH OSR Health, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1840425 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-50.4%
TTM net income YoY32.8%
TTM EPS YoY68.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin24.3%
Operating margin-946.7%
Net margin-599.0%
FCF margin—
EBITDA margin-944.8%
Returns
ROE-10.2%
ROA-5.6%
ROIC (approx.)-12.9%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets24.5%
Debt / equity0.00x
Current ratio0.15x
Interest coverage-34.95x
Cash quality & payout
Operating cash flow / net income0.48x
Accruals ratio-2.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $524,793 | $315,669 | $484,057 | $381,269 | $627,747 | $1.14M | $761,272 | $915,252 |
| Cost of revenue | $486,915 | $229,065 | $323,776 | $251,565 | $366,014 | $1.10M | $592,586 | $755,232 |
| Gross profit | $37,878 | $86,605 | $160,281 | $129,704 | $261,734 | $32,782 | $168,686 | $160,021 |
| R&D expense | $102,309 | $94,627 | $113,150 | $176,566 | -$1,794 | $53,525 | $90,149 | $14,476 |
| SG&A expense | $3.10M | $3.12M | $3.83M | $6.52M | $4.07M | $5.26M | $3.09M | $1.77M |
| Operating income | -$3.06M | -$3.03M | -$3.67M | -$6.39M | -$3.80M | -$5.23M | -$2.92M | $6.55M |
| Interest expense | $9,186 | $12,703 | $31,224 | $409,002 | $43,866 | $36,930 | $16,399 | $18,282 |
| Pretax income | -$2.37M | -$1.44M | -$3.92M | -$7.78M | -$4.49M | -$5.23M | -$11.39M | $7.99M |
| Income tax | -$464,737 | -$439,503 | -$452,314 | -$534,868 | -$1.29M | — | — | -$450,585 |
| Net income | -$1.61M | -$848,905 | -$2.93M | -$4.82M | -$2.13M | $331,414 | -$11.39M | -$2.02M |
| EBITDA | -$3.05M | -$3.02M | -$3.66M | -$6.38M | -$3.80M | -$5.23M | -$2.92M | $6.51M |
| EPS (basic) | -0.05 | -0.02 | -0.09 | — | -0.10 | 0.02 | -1.04 | — |
| EPS (diluted) | — | — | -0.08 | — | — | — | -1.04 | — |
| Weighted avg. shares (diluted) | — | — | 34.27M | — | — | — | 10.91M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.37M | $1.50M | $1.57M | $1.70M | $2.18M | $1.58M | $1.60M | $341,543 |
| Receivables | $245,458 | $188,802 | $261,362 | $319,304 | $489,181 | $742,783 | $794,507 | $904,456 |
| Inventory | $396,910 | $594,287 | $462,455 | $196,432 | $185,095 | $198,827 | $736,630 | $922,107 |
| Current assets | $2.48M | $2.87M | $2.92M | $2.82M | $3.20M | $2.88M | $3.47M | $2.33M |
| PP&E, net | $152,000 | $142,284 | $153,508 | $169,130 | $98,109 | $3,667 | $999 | $2,334 |
| Goodwill | $33.12M | $29.19M | $29.73M | $24.95M | $25.53M | $26.39M | $24.41M | $24.35M |
| Intangibles | $149.62M | $134.14M | $138.97M | $142.46M | $148.15M | $155.59M | $146.16M | $148.06M |
| Total assets | $185.77M | $166.62M | $172.19M | $171.24M | $177.29M | $185.42M | $174.55M | $175.24M |
| Current liabilities | $16.68M | $15.73M | $17.90M | $17.17M | $15.03M | $15.86M | $13.88M | $3.46M |
| Short-term debt | $298,068 | $272,701 | $196,896 | $0 | $1.86M | $630,603 | $245,482 | $1.80M |
| Long-term debt | $197,501 | $271,349 | $272,914 | $0 | $0 | — | $253,042 | $497,615 |
| Total debt | $495,569 | $544,050 | $469,810 | $0 | $1.86M | — | $498,524 | $2.30M |
| Total liabilities | $45.56M | $41.71M | $44.80M | $44.20M | $43.13M | $46.26M | $42.27M | $32.03M |
| Shareholders' equity | $117.60M | $104.27M | $103.86M | $77.64M | $81.95M | $83.70M | $75.76M | -$8.33M |
| Net debt | -$872,743 | -$955,553 | -$1.10M | -$1.70M | -$317,412 | — | -$1.10M | $1.96M |
| Shares outstanding | — | 35.12M | 33.30M | 26.60M | 23.67M | 19.81M | 19.28M | 2.15M |
| Cash flow statement | ||||||||
| Operating cash flow | -$370,518 | -$2.42M | -$1.00M | -$1.07M | -$2.71M | -$482,609 | -$64,069 | -$181,030 |
| Capital expenditure | — | — | — | — | $94,190 | — | — | — |
| Free cash flow | — | — | — | — | -$2.81M | — | — | — |
| Investing cash flow | -$187,530 | -$88,325 | $11,677 | -$2.57M | -$726,632 | -$528,424 | $1.19M | -$187,812 |
| Financing cash flow | $247,105 | $2.47M | $942,102 | $3.21M | $4.12M | $891,482 | $149,381 | $321,516 |
| Depreciation & amortization | $9,031 | $9,608 | $7,899 | $6,375 | $313 | $203 | $378 | -$41,949 |
| Share buybacks | — | — | — | — | — | — | — | $19.19M |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.